Medical Marijuana, Inc. announced a strategic alliance with AXIM Biotechnologies, Inc. focused on researching and developing applications for AXIM's patent covering water-soluble cannabinoids. The transaction centers on AXIM's U.S. Patent No. 11,542,226 B2, titled "Polyfunctional Cannabinoids," which addresses a fundamental limitation of traditional cannabinoids: their inability to dissolve in water, significantly impairing absorption by the body.
Under the agreement, AXIM assigned to MJNA a fifty percent right, title, and economic interest in the patent and all associated intellectual property. This includes rights to existing and future patents, licensing and enforcement proceeds, and claims for past infringement. MJNA paid $600,000 for this interest through a secured promissory note. Concurrently, the companies entered into a Consulting Agreement where AXIM will provide research and development services focused on developing applications for the patent technology. The agreement has an initial term of one year expiring in January 2027, with MJNA paying AXIM $62,500 per month for services.
The technological advantages of the patent could represent a significant advancement for cannabinoid-based therapies. The patented molecular engineering creates novel molecules that link cannabinoids to complementary compounds, improving delivery mechanisms and therapeutic effectiveness. These engineered polyfunctional cannabinoids are reported to be more than 300 times more water-soluble than natural cannabinoids, enabling significantly improved absorption. The technology also aims to enhance efficacy while potentially reducing toxicity, allowing for lower therapeutic doses that avoid side effects associated with higher concentrations.
Dr. Timothy R. Scott, who returned as president of MJNA in conjunction with the alliance, stated, "We have tremendous confidence in the AXIM team's ability to provide R&D support for the development of commercialized uses of the Patent technology. The potential for developing enhanced administration of water soluble CBD and other cannabinoids for certain ailments and conditions is a major development for MJNA." He noted that MJNA already has significant knowledge and exposure to the cannabinoid market and enjoys relationships in that arena.
AXIM President Catalina Valenica commented, "This alliance with MJNA presents both companies with the ability to accelerate uses of the Patent technology. The water solubility of CBD and other cannabinoids is a significant development for the improved administration and increased potency of cannabinoids. We believe that the Patent could result in the development of a drug or treatment, most likely in the form of sublingual administration, able to treat a variety of conditions including anxiety or seizures."
The expanded treatment applications could be particularly significant for conditions where traditional oil-based cannabinoids have demonstrated limited bioavailability. The technology offers potential for developing sublingual applications for anxiety and other indications, potentially creating new therapeutic options where current cannabinoid formulations face absorption challenges. This strategic alliance combines MJNA's market presence and distribution channels with AXIM's patented technology, potentially accelerating the development of next-generation cannabinoid products with improved therapeutic profiles.
